PIM3 Antikörper (C-Term)

Produktnummer ABIN2841313

Der Kaninchen Polyklonal Anti-PIM3-Antikörper wurde für WB und IHC (p) validiert. Er ist geeignet, PIM3 in Proben von Human und Maus zu detektieren. Es sind 5+ Publikationen verfügbar.

Kurzübersicht für PIM3 Antikörper (C-Term) (ABIN2841313)

Target: PIM3 (Pim-3 Oncogene (PIM3))

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PIM3 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: RB8591

Produktdetails anti-PIM3 Antikörper

Bindungsspezifität: AA 259-288, C-Term

Homologie: Rat

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This PIM3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 259-288 amino acids from the C-terminal region of human PIM3.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000. IHC-P: 1:10~50. IHC-P: 1:10~50

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Haltbarkeit: 6 months

Referenzen für anti-PIM3 Antikörper (ABIN2841313)

Ishikawa, Senba, Hashimoto, Imaizumi, Mori: "Expression and significance of Pim-3 kinase in adult T-cell leukemia." in: European journal of haematology, Vol. 99, Issue 6, pp. 495-504, (2018) (PubMed).

Decker, Finter, Forde, Kissel, Schwaller, Mack, Kuhn, Gray, Follo, Jumaa, Burger, Zirlik, Pfeifer, Miduturu, Eibel, Veelken, Dierks: "PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1)." in: Molecular cancer therapeutics, Vol. 13, Issue 5, pp. 1231-45, (2014) (PubMed).

Brault, Menter, Obermann, Knapp, Thommen, Schwaller, Tzankov: "PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma." in: British journal of cancer, Vol. 107, Issue 3, pp. 491-500, (2012) (PubMed).

Chen, Redkar, Bearss, Wierda, Gandhi: "Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells." in: Blood, Vol. 114, Issue 19, pp. 4150-7, (2009) (PubMed).

Cheng, Weidner-Glunde, Varjosalo, Rainio, Lehtonen, Schulz, Koskinen, Taipale, Ojala: "KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA." in: PLoS pathogens, Vol. 5, Issue 3, pp. e1000324, (2009) (PubMed).

Details zu PIM3

Target: PIM3 (Pim-3 Oncogene (PIM3))

Andere Bezeichnung: PIM3

Hintergrund: PIM3 is a memberof the Ser/Thr protein kinase family that may be involved in cell cycle progression and anti-apoptosis process. This protein has been implicated in proliferation of human hepatoma cell lines. PIM3 is widely expressed, with the exception of no expression observed in colon, thymus, and small intestine. PIM3 is expressed in human hepatoma cell lines but not in normal liver tissues.

Molekulargewicht: 35891

Gen-ID: 415116

NCBI Accession: NP_001001852

UniProt: Q86V86

Pathways: Negative Regulation of Hormone Secretion